StrataCTX® as a Steroid Sparing Device
NCT: NCT04087629 · RECRUITING
Publicidade
Resumo breve
The purpose is to determine if StrataCTX® can be used as a steroid sparing agent for the treatment of cutaneous reactions related to, cutaneous T Cell lymphoma (CTCL) and chemotherapy/immunotherapy treatments than the current standard treatment - topical steroids - in people who are receiving treatment for CTCL, or chemotherapy/immunotherapy for solid/hematologic malignancies. Subjects will have CTCL and are being treated with topical steroids, or being treated with chemotherapy/immunotherapy for another condition and have had cutaneous reactions that have warranted initiation of topical steroids.
Fonte oficial
Ver no ClinicalTrials.gov →Dados provenientes da API do ClinicalTrials.gov. Para consultar o estado mais recente, veja o registo oficial.